CLDX Celldex Therapeutics

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:

2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET

TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET

Live webcasts of the presentations will be available on the "” page of the "" section of the . Replays will be available for 90 days following the event.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
12/09/2024

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

Free Trial
CLDX Celldex Therape...

Celldex Therapeutics Inc: 1 director

A director at Celldex Therapeutics Inc bought 11,500 shares at 26.820USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

CLDX CELLDEX THERAPEUTICS
11/13/24 November 13, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation Conference on Tuesday, November 12th at 4:00 p.m. ET 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 4:15 p.m. ET Live webcasts of the presentations will be available on the "” page of the "" section of the . Replays will be available for 90 days following the event. About Cel...

November 11, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Third Quarter 2024 Financial Results and Provides Corp...

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of response and a favorable safety profile Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start in Q4  Celldex’s first bispecific for inflammatory diseases, CDX-622, to enter the clinic in ...

November 6, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoint...

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s Phase 2 clinical tr...

October 26, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week ...

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD)—will be presented in a late breaking oral presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) Ann...

October 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch